AngioDynamics saw no growth in patent filings and highest growth of 1.99% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 1.99%. GlobalData’s DataBook provides a comprehensive analysis of AngioDynamics‘s patent filings and grants. Buy the databook here.
AngioDynamics has been focused on protecting inventions in United States(US) with five publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 100% filings and 67% grants. The United States(US), and China(CN) patent Office are among the top ten patent offices where AngioDynamics is filings its patents. Among the top granted patent authorities, AngioDynamics has 67% of its grants in United States(US) and 33% in China(CN).
Boston Scientific and Johnson & Johnson could be the strongest competitors for AngioDynamics
Patents related to healthtech lead AngioDynamics's portfolio
AngioDynamics has the highest number of patents in healthtech. For healthtech, nearly 100% of patents were filed and 100% of patents were granted in Q2 2024.
General surgery devices related patents lead AngioDynamics portfolio followed by cardiovascular devices, and orthopedic devices
AngioDynamics has highest number of patents in general surgery devices followed by cardiovascular devices, orthopedic devices. For general surgery devices, nearly 75% of patents were filed and 75% of patents were granted in Q2 2024.
For comprehensive analysis of AngioDynamics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.